Literature DB >> 2339011

The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.

Geoffrey K Gourlay1, Stefan R Kowalski, John L Plummer, David A Cherry, Suzanne M Szekely, Laurence E Mather, Harry Owen, Michael J Cousins.   

Abstract

Forty consenting patients scheduled for abdominal surgery were entered into a double-blind comparison of the efficacy of transdermal fentanyl (TTS-fentanyl) and placebo (TTS-placebo) in the treatment of postoperative pain. All patients were allowed supplementary pethidine (25-50 mg) if pain relief was inadequate provided that their respiratory rate was greater than 10 breaths/min and there was no pronounced CNS depression. Visual analogue pain scores (VAPS), sedation rating scores (SRS), blood samples for the determination of fentanyl concentration, blood pressure, pulse and respiratory rate were determined hourly for 48 h from the time of TTS system application. The first lot of TTS systems were removed after 24 h and a second lot were applied which remained in situ for a further 24 h. There was no significant difference between the patients in the TTS-fentanyl and TTS-placebo groups in the VAPS throughout the 0-12, 12-24, 24-36 and 36-48 h periods suggesting that the quality of pain relief was similar between the 2 groups. However, significantly less supplementary pethidine was administered to the TTS-fentanyl group in the 12-24, 24-36 and 36-48 h periods. In contrast, the amount of supplementary pethidine administered in the 0-12 h period was similar in both groups which was consistent with the long delay time (mean +/- S.D. value of 16.6 +/- 10 h) before clinically effective concentrations of fentanyl were obtained from the systems. The profile of side effects was similar in the 2 groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339011     DOI: 10.1016/0304-3959(90)91046-L

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  14 in total

Review 1.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers.

Authors:  Hee Youn Choi; Yo Han Kim; Donghyun Hong; Seong Su Kim; Kyun-Seop Bae; Hyeong-Seok Lim
Journal:  Eur J Clin Pharmacol       Date:  2015-05-28       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 4.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

5.  Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia.

Authors:  K A Lehmann; C Einnolf; H J Eberlein; R Nagel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Pharmacokinetic characterisation of transdermal delivery systems.

Authors:  B Berner; V A John
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

7.  Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.

Authors:  Carla Ripamonti; Elena Fagnoni; Tiziana Campa; Cinzia Brunelli; Franco De Conno
Journal:  Support Care Cancer       Date:  2006-02-17       Impact factor: 3.603

8.  [Drug therapy for tumor pain I. Properties of non-opioids and opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1994-12       Impact factor: 1.107

9.  [Pharmacotherapy of cancer pain : 2. Use of opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

Review 10.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.